[go: up one dir, main page]

WO2025061618A1 - Dispositif d'administration de médicament - Google Patents

Dispositif d'administration de médicament Download PDF

Info

Publication number
WO2025061618A1
WO2025061618A1 PCT/EP2024/075788 EP2024075788W WO2025061618A1 WO 2025061618 A1 WO2025061618 A1 WO 2025061618A1 EP 2024075788 W EP2024075788 W EP 2024075788W WO 2025061618 A1 WO2025061618 A1 WO 2025061618A1
Authority
WO
WIPO (PCT)
Prior art keywords
medicament delivery
actuator
delivery device
housing
manually operable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/075788
Other languages
English (en)
Inventor
Nurettin Ali
Amit Singh
Daniel Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHL Medical AG
Original Assignee
SHL Medical AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHL Medical AG filed Critical SHL Medical AG
Publication of WO2025061618A1 publication Critical patent/WO2025061618A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31501—Means for blocking or restricting the movement of the rod or piston
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31566—Means improving security or handling thereof
    • A61M5/3157—Means providing feedback signals when administration is completed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31566—Means improving security or handling thereof
    • A61M5/31571—Means preventing accidental administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
    • A61M5/31578—Constructional features or modes of drive mechanisms for piston rods based on axial translation, i.e. components directly operatively associated and axially moved with plunger rod
    • A61M5/3158—Constructional features or modes of drive mechanisms for piston rods based on axial translation, i.e. components directly operatively associated and axially moved with plunger rod performed by axially moving actuator operated by user, e.g. an injection button
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/2073—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically preventing premature release, e.g. by making use of a safety lock

Definitions

  • the present disclosure relates to a medicament delivery device and in particular, but not exclusively, to a medicament delivery device that has improved handling.
  • Medicament delivery devices maybe activated by depression of a medicament delivery member cover (needle cover) or a combination of a needle cover and an activation button. Although such mechanisms ensure that the device is activated on the injection site, activation, in particular depression of the needle cover, maybe challenging in case of a soft tissue at the injection site.
  • the present disclosure addresses such problems.
  • a medicament delivery device comprises a housing arranged to accommodate a medicament container and a power pack arranged to exert a force on said medicament container for expelling a dose of medicament.
  • the power pack comprises a plunger rod, a drive spring arranged to exert a force on said plunger rod in a proximal direction, wherein the proximal direction is a direction towards a medicament delivery site, an actuator coaxial with said plunger rod and arranged with holding elements for releasably holding said plunger rod with said drive spring in an energised state and further comprising at least one blocking element provided towards a distal end of the actuator, a manually operable activator arranged at a distal end of the housing movable in the proximal direction, rotatable around a central longitudinal axis of the housing and operably connected to said actuator for releasing said plunger rod, wherein the manually operable activator comprises at least one stop provided at a circumferential surface thereof, wherein the housing comprises an internal locking surface, wherein in
  • the stop is configured to clear the blocking element.
  • the manually operable activator comprises at least one rotation protrusion protruding from an outer circumferential surface thereof.
  • the housing comprises a recess configured to receive the rotation protrusion.
  • the recess is substantially L-shaped.
  • the recess is provided on an inner circumferential surface of the housing and is formed by two parallel recesses extending in the circumferential direction of the housing.
  • the rotation protrusion is configured to visually indicate the first or second rotational state of the manually operable activator.
  • the rotation protrusion protrudes through the recess to provide visual and tactile indication of the first or second rotational state.
  • the rotation protrusion in the first rotational state, is configured to abut a proximal surface of the recess, thus blocking proximal movement of the manually operable activator.
  • the recess comprises a ridge extending in the circumferential direction of the housing and dividing the recess in a proximal part and a distal part.
  • the rotation protrusion is a snap flexible in a radial direction with respect to the central longitudinal axis.
  • the snap is configured to flex inwards in the radial direction to pass the ridge, when the manually operable activator is pushed proximally.
  • the manually operable activator comprises a proximally directed contact point and the actuator comprises a corresponding distally directed contact point,
  • the actuator is configured to be pushed proximally by operation of the manually operable activator via abutment of the activator contact point and the actuator contact point.
  • the blocking element is a protrusion, preferably protruding radially outwards with respect to the central longitudinal axis of the housing.
  • the stop is a protrusion, preferably protruding radially towards the central longitudinal axis of the housing, and more preferably the stop comprises a circular ring segment.
  • the proximally directed surface of the manually operable activator is a proximal end surface of the manually operable activator.
  • the internal locking surface is provided on a protrusion that preferably protrudes radially towards the central longitudinal axis of the housing, and more preferably the internal locking surface comprises a circular ring segment.
  • the medicament delivery device further comprises an actuator sleeve coaxial with said actuator.
  • the actuator sleeve is arranged to interact with said holding elements, said actuator sleeve being movable in a longitudinal direction in relation to the actuator and the housing.
  • the medicament delivery device further comprises a medicament delivery member cover protruding from the proximal end of said housing and movable in said longitudinal direction.
  • the actuator is moveable in a longitudinal direction with respect to the housing and the actuator sleeve between an initial state, an activated state and an end state.
  • the actuator in the initial state, is located further proximal than in the end state, and in the activated state the actuator is located further proximal than in the initial state with respect to the housing.
  • the actuator sleeve comprises a first recess and a second recess on an inner circumferential surface wherein the first recess is located further towards the proximal end than the second recess.
  • the holding elements of the actuator comprises two proximally directed arms that are flexible in a generally radial direction and wherein the arms are arranged with outwardly directed surfaces engaging an inner surface of said actuator sleeve.
  • the outwardly directed surfaces are located in the first recess blocking outward movement of the arms.
  • the holding elements of the actuator comprise two proximally directed arms that are flexible in a generally radial direction, wherein the arms are arranged with inwardly directed protrusions engaging corresponding recesses in said plunger rod in the initial state.
  • the outwardly directed surfaces disengage the first recess allowing the arms to flex outwardly and the inwardly directed protrusions are configured to disengage corresponding recesses of the plunger rod allowing the plunger rod to be moved in the proximal direction by force of the drive spring.
  • the arms are configured to flex radially inwards during distal movement of the actuator and the actuator is configured to be pushed in the distal direction by a residual force of the drive spring.
  • a distally directed surface of the actuator is configured to hit a proximally directed surface of the housing, giving an audible and/or tactile signal.
  • a distally directed surface of the actuator is configured to abut a proximally directed surface of the housing.
  • the actuator sleeve is moveable in a longitudinal direction with respect to the housing between an initial state and a locked state.
  • the actuator sleeve is located further proximal with respect to the housing than in the initial state.
  • the actuator sleeve comprises at least one retaining element provided towards a distal end of a flexible arm and configured to abut a distally directed surface of the housing in the initial state of the actuator sleeve, thus blocking proximal movement of the actuator sleeve with respect to the housing.
  • the distally directed surface is a collar.
  • the distally directed surface protrudes radially inwards.
  • an outer circumferential surface of the actuator blocks inward movement of the retaining element.
  • the actuator comprises at least one release recess corresponding to the at least one retaining element.
  • the at least one release recess is configured to allow the at least one retaining element to flex inwardly, wherein the retaining element disengages the distally directed surface thus allowing the actuator sleeve to move proximally to the locked state.
  • the outwardly directed surfaces of the actuator engage the second recess of the actuator blocking proximal movement of the arms and thus the actuator.
  • an actuator sleeve spring is provided to exert a proximally directed force on the actuator sleeve.
  • the medicament delivery member cover is coupled to the actuator sleeve.
  • the medicament delivery device comprises an injection needle, wherein in the locked state of the actuator sleeve, the medicament delivery member cover is configured to cover the injection needle.
  • the power pack comprises a guide rod provided with fastening elements at its distal end, which fastening elements engage cut-outs on the actuator.
  • the drive spring is arranged between a proximal end wall of the plunger rod and the fastening elements.
  • the manually operable activator further comprises at least one proximally extending leg configured to block distal movement of the manually operable activator with respect to the housing.
  • the proximally extending leg comprises at least one locking protrusion configured to engage a collar provided at an inner circumferential surface of the housing.
  • the collar comprises a leg recess through which the proximally extending legs extend.
  • the leg recess is formed between the collar and an inner circumferential surface of the housing.
  • the at least one locking protrusion is configured to engage a proximally directed surface of the collar.
  • the medicament delivery device further comprises a syringe holder configured to accommodate the medicament container and a cap removably attached to the housing.
  • the syringe holder comprises at least one flexible syringe holder arm configured to block proximal movement of the syringe holder when the cap is attached to the housing.
  • the at least one flexible syringe holder arm is configured to engage a syringe holder recess provided at an inner circumferential surface of the housing.
  • the cap is configured to block an inward radial movement of the at least one flexible syringe holder arm.
  • the at least one flexible syringe holder arm is configured to flex inwards towards the central longitudinal axis and is configured to clear the syringe holder recess to allow proximal movement of the syringe holder.
  • distal direction refers to the direction pointing away from the dose delivery site during use of the medicament delivery device.
  • distal part/end refers to the part/end of the delivery device, or the parts/ends of the members thereof, which during use of the medicament delivery device is/are located furthest away from the dose delivery site.
  • proximal direction refers to the direction pointing towards the dose delivery site during use of the medicament delivery device.
  • proximal part/end this refers to the part/end of the delivery device, or the parts/ends of the members thereof, which during use of the medicament delivery device is/are located closest to the dose delivery site.
  • the terms “longitudinal”, “longitudinally”, “axially” and “axial” refer to a direction extending from the proximal end to the distal end and along the device or components thereof, typically in the direction of the longest extension of the device and/or component.
  • the direction may also be referred to as x-axis/x-direction.
  • the proximal direction may be referred to as the negative x-direction and the distal direction may be referred to as the positive x-direction.
  • the terms “transverse”, “transversal” and “transversally” refer to a direction generally perpendicular to the longitudinal direction.
  • the y-axis and the z-axis maybe perpendicular to the x-axis.
  • circumference refers to a circumference or a circumferential direction relative to an axis, typically a central (longitudinal) axis extending in the direction of the longest extension of the device and/or component.
  • radial refers to a direction extending radially relative to the axis
  • rotation refers to rotation relative to the axis.
  • Figure 1 is an exploded view of some components of a medicament delivery device according to an embodiment of the present disclosure.
  • Figures 2A to 2F are views of different rotational and axial states of a manually operable activator according to an embodiment of the present disclosure.
  • Figure 3A is a perspective view of a housing according to an embodiment of the present disclosure.
  • Figures 3B and 3C are perspective cross-sectional views of a housing and a manually operable activator in different rotational states according to an embodiment of the present disclosure.
  • Figure 4 is an exploded perspective view of a manually operable activator and an actuator according to an embodiment of the present disclosure.
  • Figure 5A is a cross sectional view of a manually operable activator and figure 5B is a cross sectional view of the manually operable activator and the actuator according to an embodiment of the present disclosure.
  • Figure 6A is a side view of an actuator sleeve
  • figure 6B is a cross sectional view of the actuator sleeve
  • Fig. 6C is a perspective cross sectional view according to an embodiment of the present disclosure.
  • Figure 7 is an exploded perspective view of an actuator sleeve, an actuator and a plunger rod according to an embodiment of the present disclosure.
  • Figure 8 is a cross sectional view of an actuator, an actuator sleeve and a plunger rod according to an embodiment of the present disclosure.
  • Figure 9 is a partial cross-sectional view of a medicament delivery device according to an embodiment of the present disclosure.
  • Figures 10 to 13 are cross sectional views showing an injection sequence of a medicament delivery device according to an embodiment of the present disclosure.
  • Figure 14 is a partial perspective view of a rear part according to an embodiment of the present disclosure.
  • Figure 15A is a perspective view of a manually operable activator according to an embodiment of the present disclosure.
  • Figure 15B is a cross sectional view of Fig. 15A.
  • Figures 16A and 16B are partial cross sectional views of a distal part of a medicament delivery device according to an embodiment of the present disclosure.
  • Figure 17 is a perspective view of a distal housing part according to an embodiment of the present disclosure.
  • Figure 18 is a partial perspective view of a distal part of a medicament delivery device according to an embodiment of the present disclosure.
  • Figure 19 is an exploded perspective view of a cap and a syringe holder according to an embodiment of the present disclosure.
  • Figures 20 and 21 are cross sectional views of a proximal part of a medicament delivery device according to an embodiment of the present disclosure.
  • the medicament delivery device according to the present disclosure may comprise an activation mechanism similar to the one shown in WO 2020/143991 Al and a detailed description thereof, unless necessary, may be omitted.
  • a medicament delivery device as disclosed herein and as shown in the exploded view of Fig. 1 comprises a housing 1 arranged to accommodate a medicament container, e.g., a syringe 7, and a power pack arranged to exert a force on said medicament container for expelling a dose of medicament. That is, the medicament delivery device may comprise a housing 1 and a power pack and the housing 1 may be arranged to accommodate a medicament container and may be arranged to accommodate the power pack.
  • the housing 1 maybe provided as one housing part or subdivided in a plurality of subhousings, e.g., a front housing (proximal housing) and rear housing (distal housing).
  • a front housing proximal housing
  • rear housing distal housing
  • the description of the embodiments is based on a two-part housing (front housing and rear housing 1) but the present disclosure is not limited to this configuration.
  • a cap 8 which may also function as a needle shield remover is provided on a proximal end of the medicament delivery device and a manually operable activator 2 is provided on a distal end of the medicament delivery device.
  • the syringe 7 is held by a syringe holder 71 and surrounded by a medicament delivery member cover 5.
  • the power pack comprises a plunger rod 6 (see Fig. 7) and a drive element, e.g. a drive spring, (not shown) arranged to exert a force on said plunger rod 6 in a proximal direction.
  • a drive element e.g. a drive spring
  • An actuator 3 is coaxially provided with said plunger rod 6 and arranged with holding elements 31 (see Fig. 4) for releasably holding said plunger rod 6 with said drive spring in an energised state.
  • the holding elements 31 maybe provided towards the proximal end of the actuator 3 and will be further described later on.
  • At least one blocking element 33 is provided towards a distal end of the actuator 3.
  • the manually operable activator 2 is arranged at a distal end of the housing 1 and is movable in the proximal direction, rotatable around a central longitudinal axis of the housing 1 and operably connected to said actuator 3 for releasing said plunger rod.
  • the manually operable activator 2 maybe, e.g., a push button, activation button or the like.
  • the manually operable activator 2 comprises at least one stop 23 (not shown in Fig. 1, see Figs. 3B, 3C) provided at a circumferential surface thereof.
  • the housing 1 comprises an internal locking surface 11 (not shown in Fig. 1) to be further described later on.
  • a proximally directed surface 21 (see Figs. 3B, 3c) of the manually operable activator 2 abuts the locking surface 11 of the housing 1 blocking proximal movement of the manually operable activator 2 with respect to the housing 1 and the blocking element 33 of the actuator 3 is configured to abut the stop 23 thus blocking proximal movement of the actuator 3 with respect to the manually operable activator 2.
  • the proximally directed surface 21 of the manually operable activator 2 is configured to clear the locking surface 11 of the housing 1 and the manually operable activator 2 is free to be displaced in the proximal direction on application of a force by a user.
  • the stop 23 maybe configured to clear the blocking element 33.
  • the actuator 3 is located coaxially inside an actuator sleeve 4 to be described later.
  • Figs. 2A to 2F show partial views of a distal end of the medicament delivery device according to an embodiment.
  • Figs. 2A to 2F show different rotational states of the manually operable activator 2.
  • the manually operable activator 2 comprises at least one rotation protrusion 22 protruding from an outer circumferential surface thereof and the housing 1 comprises a recess 12 configured to receive the rotation protrusion 22.
  • the rotation protrusion 22 protrudes in a radial outward direction from the manually operable activator 2 and is formed in a knob or bolt shape.
  • the rotation protrusion 22 protrudes in a radial outward direction from the manually operable activator 2 and is formed as a snap. That is, the proximally directed side of the rotation protrusion maybe tapered in the radial inward direction, i.e., towards the central axis.
  • the recess 12 maybe substantially L-shaped. That is, the two legs of the L-shape of the recess 12 may extend in the circumferential direction and the proximal direction of the housing 1, respectively.
  • a ridge 17 (activator ridge 17) extending in the circumferential direction of the housing 1 may be provided. The ridge 17 may divide the recess 12 in a proximal part 171 and a distal part 172.
  • Figs. 2A and 2D show the manually operable activator 2 in the first rotational state while Figs. 2B, 2C, 2E and 2F show the manually operable activator 2 in the second rotational state in which the manually operable activator 2 has been rotated with respect to the housing 1 around the central axis.
  • Figs. 2A and 2D show the medicament delivery device in a locked state (no triggering of the device possible), Figs. 2B and 2E in an unlocked state (triggering of the device possible) and Figs. 2C and 2F in an activated state (medicament delivery in process), in which the manually operable activator 2 has been pushed in the proximal direction.
  • the rotation protrusion 22 may be configured to visually indicate the first or second rotational state of the manually operable activator 2.
  • the rotation protrusion 22 may protrude through the recess 12 to provide visual and tactile indication of the first or second rotational state.
  • the rotation protrusion 22 may give an indication of the locked state, the unlocked state and the activated state.
  • the rotation protrusion 22 in the first rotational state, is configured to abut a proximal surface of the recess 12, thus blocking proximal movement of the manually operable activator 2. This may be a further safety mechanism in addition to the proximally directed surface 21 of the manually operable activator 2 abutting the locking surface 11 of the housing 1.
  • the snap (rotation protrusion 22) is flexible in a radial direction with respect to the central longitudinal axis. This may also be the case for the rotation protrusion 22 shown in Figs. 2A to 2C.
  • the rotation protrusion 22 maybe provided on a flexible bar having cut-outs around the circumference allowing flexibility in the radial direction (see Fig. 4).
  • the snap (rotation protrusion 22) is configured to flex inwards in the radial direction to pass the ridge 17 when the manually operable activator 2 is pushed proximally from the unlocked state to the activated state.
  • the rotation protrusion 22 is thus pushed from the proximal part 171 to the distal part 172, passing the ridge 17.
  • the snap may prevent distal movement of the manually operable activator 2 due to the abutment of the snap 22 on the ridge 17.
  • the housing recess 12 may further comprise a proximally directed protrusion 18 preventing inadvertent rotation of the manually operable activator/ member 2 from the first rotational state to the second rotational state.
  • the housing recess 12 may not be cut out through the housing 1 but rather provided only on an inner circumferential surface of the housing 1 as shown in Fig. 14. Therein, the housing 1 is shown transparently allowing to view the inner circumferential surface thereof.
  • the recess 12 may be substantially formed in an L- shape as described above or, as shown in Fig. 14, as two recesses 12 extending in the circumferential direction of the housing 1.
  • the two recesses 12 may be separated by a ridge 17.
  • the recess 12 maybe separated in a proximal part 171 and a distal part 172 by the ridge 17.
  • the snap rotation protrusion 22
  • the snap may be configured to flex inwards in the radial direction to pass the ridge 17 when the manually operable activator 2 is pushed proximally from the unlocked state to the activated state.
  • Fig. 3A shows a perspective view of a housing 1 according to an embodiment. In this case, a rear housing 1 (distal housing) is shown but the disclosure is not limited thereto and the housing 1 may also be provided as a single piece.
  • the internal locking surface 11 is provided as a protrusion that may protrude radially towards the central longitudinal axis of the housing 1 (see Fig. 3A).
  • the internal locking surface 11 may comprise a circular ring segment as shown in Fig. 3A.
  • the internal locking surface 11 is provided as four protrusions equally distributed around the inner circumference of the housing 1, i.e., each offset by 90°.
  • Fig. 3A further shows a distally directed surface 13 of the housing 1.
  • the distally directed surface 13 may be provided at an inner circumferential surface of the housing
  • the distally directed surface 13 may be a collar 13.
  • the internal locking surface 11 may also be provided on the collar 13 and protrude in a distal direction therefrom.
  • Figs. 3B and 3C show a partial perspective view of the distal part of the medicament delivery device, in particular the housing 1, the manually operable activator 2 and the actuator 3.
  • the manually operable activator 2 is shown in a cross section allowing to view the interior of the device.
  • the cross section is perpendicular to the central axis, i.e., in the y-z-plane.
  • the proximally directed surface 21 of the manually operable activator 2 may be a proximal end surface of the manually operable activator 2. In the first rotational state shown in Fig. 3B, the proximally directed surface 21 of the manually operable activator
  • the proximally directed surface 21 of the manually operable activator 2 clears the locking surface 11 of the housing 1 and the manually operable activator 2 is free to be displaced in the proximal direction on application of a force by a user.
  • the manually operable activator 2 may also comprise an activation recess 26 corresponding to the internal locking surface 11.
  • the activation recess 26 may be recessed from a proximal surface, e.g., a proximal end surface, of the manually operable activator 2 in the distal direction.
  • the proximally directed surface 21 clears the internal locking surface 11 and the activation recess 26 receives the internal locking surface 11 when the manually operable activator 2 is moved in the proximal direction for activation of the medicament delivery device (see Fig. 3C).
  • Fig. 4 is an exploded perspective view of the manually operable activator 2 and the actuator 3 according to an embodiment. Some of the features of the manually operable activator 2 has already been described above and will not be repeated.
  • the manually operable activator 2 further comprises a proximally directed contact point 25 and the actuator 3 comprises a corresponding distally directed contact point 35.
  • the distally directed contact point 35 is provided on the inside of the actuator 3 and not shown in Fig. 4 but will be further described below (see Fig. 5B).
  • the actuator 3 In the second rotational state, the actuator 3 is configured to be pushed proximally by operation of the manually operable activator 2 via abutment of the activator contact point 25 and the actuator contact point 35.
  • the actuator’s 3 blocking element 33 is a protrusion which may protrude radially outwards with respect to the central longitudinal axis of the housing 1. In the locked state of the manually operable activator 2, the blocking element 33 abuts the stop 23 of the manually operable activator 2 to prevent proximal movement of the actuator.
  • the actuator 3 further comprises a release recess 34 interacting with the actuator sleeve 4 as described below.
  • At least one holding element 31 is provided. In an embodiment, two or four equally distributed holding elements 31 may be provided.
  • the holding elements 31 may be formed as flexible arms capable of flexing in the radial direction with respect to the central axis.
  • outwardly directed surfaces 312 may be provided interacting with the actuator sleeve 4.
  • inwardly directed protrusions 311 interacting with the plunger rod 6 may be provided towards the proximal end of the holding elements 31.
  • a proximal (end) surface 313 maybe provided at the proximal end of the holding elements 31.
  • the actuator 3 may further comprise a feedback protrusion 36.
  • the feedback protrusion 36 may protrude in a radial outward direction from a centre portion of the actuator 3. After medicament delivery, the feedback protrusion 36 hits a corresponding surface of the housing 1 to generate an audible and/or tactile signal that medicament delivery is completed.
  • the housing 1 surface maybe, e.g., the proximal side of the collar 13 (see Fig. 12) or the proximal side of the distally directed surface 13, respectively.
  • Fig. 5A is a perspective cross sectional view of the manually operable activator 2 along the central longitudinal axis and Fig. 5B is a perspective cross sectional view of the manually operable activator 2 in interaction with the actuator 3 along the central longitudinal axis.
  • the stop 23 is a protrusion. Said protrusion may protrude radially towards the central longitudinal axis of the housing 1.
  • the stop 23 may comprise a circular ring segment. That is, the stop 23 may not extend around the complete inner circumference of the manually operable activator 2.
  • the blocking element 33 is located at a position corresponding to the stop 23 and is in contact therewith to block relative proximal movement between the actuator 3 and the manually operable activator 2.
  • the stop 23 and the blocking element 33 respectively may be provided in plural.
  • the activator contact point 25 may be provided on one or more proximally extending legs 251.
  • the legs maybe provided coaxially with an outer circumference of the manually operable activator 2.
  • the legs 251 may be flexible in the radial direction. In the initial state (locked/unlocked state), i.e., before medicament delivery, the plunger rod 6 prevents the proximally extending legs 251 having the contact points 25 from flexing radially inwards.
  • the corresponding actuator contact point(s) 35 are provided on an inner circumferential surface of the actuator 3.
  • the contact points 25, 35 may be in contact with each other in the first and second rotational state as well as the locked state, the unlocked state and the activated state. Through this contacting surface, and since the proximally extending legs 251 cannot flex radially, a proximal movement of the manually operable activator 2 with respect to the housing 1 is transferred to the actuator 3 and both elements can be moved together in the proximal direction.
  • Both contact points 25, 35 may be tapered.
  • the blocking element 33 it is not necessary that the blocking element 33 fully clears the stop 23 in the second rotational state since there is no proximal relative movement of the actuator 3 with respect to the manually operable activator 2 in the activated state.
  • the actuator 3 can move in the distal direction, e.g., for generating a feedback signal to be described below.
  • the medicament delivery device further comprises an actuator sleeve 4 as shown in Fig. 6A coaxial with said actuator 3.
  • an actuator sleeve 4 as shown in Fig. 6A coaxial with said actuator 3.
  • the retaining element 43 may be located at or towards a distal end of a flexible arm 431 extending from the actuator sleeve 4 in the distal direction.
  • the retaining element 43 may be configured to abut a distally directed surface 13 (see Figs. 3A, 9) of the housing 1 to block proximal movement of the actuator sleeve 4 relative to the housing 1.
  • the actuator sleeve 4 is arranged to interact with said holding elements 31 (see Fig. 4).
  • the actuator sleeve 4 is movable in a longitudinal direction in relation to the actuator 3 and the housing 1.
  • a first recess 41 and a second recess 42 may be provided at an inner circumferential surface of the actuator sleeve 4. As can be seen from the cross sectional view of the actuator sleeve 4 in Fig. 6B, the first recess 41 and the second recess 42 may also be formed between at least one longitudinally extending ridge 45 and may be recessed in the radial outward direction with respect to said ridge 45. The first recess 41 is located further towards the proximal end of the actuator sleeve 4 than the second recess 42.
  • first recess 41 may be formed as a proximal inner surface of the actuator sleeve 4 and the second recess 42 maybe formed as a distal inner surface of the actuator sleeve 4.
  • Fig. 7 is an exploded perspective view of the actuator sleeve 4 and the actuator 3 as described above as well as the plunger rod 6.
  • the plunger rod 6 may comprise a plunger rod recess 611 interacting with the inwardly directed protrusion 311 of the actuator 3.
  • Fig. 8 is a cross sectional view along the central longitudinal axis of the medicament delivery device showing the plunger rod 6, the actuator 3 and the actuator sleeve 4 in an assembled and locked state according to an embodiment.
  • the actuator 3 is moveable in a longitudinal direction (x-direction) with respect to the housing 1 and the actuator sleeve 4 between an initial state, an activated state and an end state. In the initial state, the actuator 3 is located further proximal than in the end state, and in the activated state the actuator 3 is located further proximal than in the initial state with respect to the housing 1. In Fig. 8, the initial state is shown.
  • the actuator sleeve 4 comprises a first recess 41 and a second recess 42 on an inner circumferential surface wherein the first recess 41 is located further towards the proximal end than the second recess 42.
  • a distally directed surface of the outwardly directed surface 312 may abut the ridge 45 shown in Fig. 6B (which is hidden in the view of Fig. 8), i.e., a proximally directed surface of the ridge 45.
  • the recesses 41 and 42 may also be formed by an inner circumferential surface of the actuator sleeve 4 and thus be recessed in the radial outward direction with respect to the ridge 45 as described above.
  • the holding elements 31 of the actuator 3 may comprise two or more proximally directed arms that are flexible in a generally radial direction and the arms may be arranged with the outwardly directed surfaces 312 engaging an inner surface of said actuator sleeve 4.
  • Said inner surface of the actuator sleeve 4 may be the first recess 41.
  • the outwardly directed surfaces 312 may be located in the first recess 41 blocking outward movement of the arms.
  • the two or more proximally directed arms may further be arranged with the inwardly directed protrusions 311 engaging corresponding recesses 611 in said plunger rod 6 in the initial state. Furthermore, in the initial state and the first rotational state of the manually operable activator 2, the blocking element 33 is in engagement with the stop 23 and the retaining element 43 is in engagement with the distally directed surface 13.
  • Fig. 9 is a partial cross sectional view of a medicament delivery device according to an embodiment of the disclosure.
  • the proximal part of the device is not depicted.
  • Fig. 9 shows the device in the first rotational state of the manually operable activator 2 and the initial state of the actuator 3. The device is thus locked and a medicament delivery has not yet been performed.
  • the power pack comprises a plunger rod 6 and a drive spring 63 arranged to exert a force on said plunger rod 6.
  • a guide rod 62 is coaxially provided in the plunger rod 6, wherein the drive spring 63 is arranged around said guide rod 62.
  • the guide rod 62 is provided with fastening elements 621 at the distal end of the guide rod 62.
  • the fastening elements 621 fix the guide rod 62 relative to the actuator 3.
  • the fastening elements 621 may engage respective cut-outs of the actuator 3.
  • the drive spring 63 is arranged between a proximal end wall of the plunger rod 6 and the fastening elements 621.
  • the plunger 6 having a stopper 64 at the proximal end to deliver a drug provided in the syringe is pushed in the proximal direction by the force of the drive spring 63 but held by the engagement of the inwardly directed protrusion 311 and the plunger rod recess 611 preventing relative proximal movement of the plunger rod 6 with respect to the actuator 3.
  • the syringe 7 comprises a needle (medicament delivery member) for injecting a drug into a patient.
  • the medicament delivery device further comprises a medicament delivery member cover 5 protruding from the proximal end of the housing 1 and being movable in the longitudinal direction.
  • the process of medicament delivery will be described with reference to Figs. 10 to 13 showing an embodiment.
  • the disclosed medicament delivery device is provided particularly for soft tissue, i.e., a soft injection surface. Since it may be difficult to compress a medicament delivery member cover spring on a soft injection site, the present medicament delivery device is triggered only by the manually operable activator 2.
  • the rotating manually operable activator 2 as described above is provided which can only be actuated after turning it into the second rotational state.
  • Figs. 10 to 12 are rotated 90 degrees around the central longitudinal axis with respect to Fig. 9. Some parts such as the proximal housing, the syringe 7, the stopper 64, the medicament delivery member cover 5, etc. have been omitted in the following figures 10 to 13.
  • the figures also show a syringe driver 72 which functions similarly as described in WO 2020/143991 Al.
  • the manually operable activator 2 has been turned into the second rotational state (unlocked state) and the actuator 3 is still in the initial state.
  • the device is ready to be triggered by pushing the manually operable activator 2 in the proximal direction through a force of a user.
  • the force exerted on the manually operable activator 2 is transferred to the actuator 3 via the contact points 25, 35 and the actuator 3 is pushed in the proximal direction the same distance the manually operable activator 2 is moved.
  • the syringe holder 71 together with the syringe 7 are moved proximally to pierce a patient’s skin.
  • the syringe 7 may be axially fixed with respect to the syringe holder 71.
  • the outwardly directed surfaces 312 of the actuator 3 disengage the first recess 41 allowing the arms to flex outwardly. Consequently, the inwardly directed protrusions 311 disengage the corresponding recesses 611 of the plunger rod 6 allowing the plunger rod 6 to be moved in the proximal direction by force of the drive spring 63.
  • the plunger rod 6, together with the stopper 64, pushes the medicament out of the syringe 7 for delivery into a patient’s tissue.
  • the actuator 3 When a distal end of the plunger rod 6 has passed the inwardly directed protrusions 311 during proximal movement of the plunger rod 6, the actuator 3 is pushed in the distal direction by a residual force of the drive spring 63 and the arms are configured to flex radially inwards during distal movement of the actuator 3.
  • the outwardly directed surface 312 is able to pass the first recess 41 (proximal inner surface 41) or the ridge 45, respectively, since the plunger rod 6 does not hinder the arms from flexing radially inwards. Since the contact points 25 of the manually operable activator 2 and the corresponding contact points 35 of the actuator 3 maybe tapered, the distal movement of the actuator
  • a distally directed surface of the actuator 3 is configured to hit a proximally directed surface of the housing 1, giving an audible and/or tactile signal.
  • the distally directed surface of the actuator 3 maybe the feedback protrusion 36 described above and the proximally directed surface of the housing may be a proximal side of the distally directed surface 13, e.g., the collar 13. The actuator 3 is in the end state.
  • the distally directed surface of the actuator e.g., the feedback protrusion 36
  • Fig. 12 is an angled cross sectional view and shows the configuration after the plunger rod 6 has been fully extended, i.e., moved proximally. Moreover, the proximally extending legs 251 having the contact points 25 have been flexed radially inwards allowing the actuator 3 to be fully moved in the distal direction as described above.
  • the actuator sleeve 4 is moveable in a longitudinal direction with respect to the housing 1 between an initial state and a locked state. Before and during medicament delivery (locked/ unlocked/ activated state of the actuator 3), the actuator sleeve 4 is in the initial state. After medicament delivery, the actuator sleeve 4 can be moved to the locked state. In the locked state, the actuator sleeve 4 is located further proximal with respect to the housing 1 than in the initial state.
  • An actuator sleeve spring 44 is provided to exert a proximally directed force on the actuator sleeve 4. In other words, the actuator
  • the actuator sleeve spring 44 may also be referred to as a medicament delivery member cover spring or needle cover spring.
  • the actuator sleeve 4 comprises at least one retaining element 43 provided towards the distal end of a flexible arm and configured to abut the distally directed surface 13 of the housing 1 in the initial state of the actuator sleeve 4 (see Fig. 9). Thereby, proximal movement of the actuator sleeve 4 with respect to the housing 1 is blocked.
  • the actuator 3 comprises at least one release recess 34 corresponding to the at least one retaining element 43.
  • the release recess 34 is located further proximal than the outer circumferential surface of the actuator 3 blocking inward movement of the retaining element 43.
  • the actuator 3 In the end state of the actuator 3 as shown in Fig. 12, the actuator 3 has been moved distally and the release recess 34 is on the same axial height as the retaining element 43.
  • the at least one release recess 34 is configured to allow the at least one retaining element 43 to flex inwardly. Consequently, the retaining element 43 disengages the distally directed surface 13.
  • the actuator sleeve 4 is able to be moved proximally to the locked state by the force of the actuator sleeve spring 44.
  • the contact surfaces of the retaining element 43 and the distally directed surface 13 (or collar 13) may be tapered.
  • the actuator sleeve retaining elements 43 are aligned with the release recess 34 on the actuator 3.
  • the actuator sleeve retaining elements 43 flex in and release the actuator sleeve 4.
  • the actuator sleeve spring 4 extends, the actuator sleeve 4 moves forward and pushes the medicament delivery member cover 5 out.
  • the retaining elements 43 on the actuator sleeve 4 allow the medicament delivery member cover 5 to be locked till the end of the dose and the feedback signal/click.
  • Fig. 13 is a cross sectional view of an end state of the medicament delivery device, i.e., after medicament delivery, according to an embodiment.
  • the manually operable activator 2 is in the activated state, the actuator 3 is in the end state and the actuator sleeve 4 is in the locked state.
  • the ridge 45 as described above is provided on the inner circumferential surface of the actuator sleeve 4, the outwardly directed surface 312 contacts the distal inner surface 42 and the proximal (end) surface 313 of the actuator 3 abuts or engages a distal end of the ridge 45.
  • the proximal (end) surface 313 of the actuator 3 and the distal end of the ridge 45 maybe reversely tapered to lock the actuator sleeve 4 in place.
  • the actuator 3 is locked inside the actuator sleeve 4.
  • the medicament delivery member cover 5 may be coupled to the actuator sleeve 4.
  • delivery member cover 5 is moved proximally together with the actuator sleeve 4. Due to the resulting proximal extension of the medicament delivery member cover 5, in the locked state of the actuator sleeve
  • the medicament delivery member cover 5 covers the injection needle to prevent a user from reaching or touching the needle. Hence, injuries after injection may be provided.
  • the manually operable activator 2 may be provided without the rotation protrusion and thus the recess of the housing 1, formed as a cut-out or internal recess, may be omitted.
  • the functionality is not altered and the locking mechanism between the manually operable activator 2 and the housing 1 is provided as outlined above.
  • FIG. 15A and 15B A manually operable activator 2 without rotation protrusion is shown in Figs. 15A and 15B, wherein Fig. 15B is a cross section of Fig. 15A.
  • the stop 23, the proximally directed surface 21, the activation recess 26 and the legs 251 having the activator contact point 25 are provide as explained above and further description will be omitted.
  • the manually operable activator 2 may further comprise at least one second leg 27.
  • the at least one second leg 27 may extend proximally.
  • the at least one second leg 27 may extend from an outer circumferential surface of the manually operable activator 2 in a proximal direction.
  • the at least one second leg 27 may extend parallel to the at least one leg 251 and may for example be offset by 90 degrees with respect to the at least one leg 251 in a circumferential direction.
  • the at least one second leg 27 may extend into the housing 1 as will be shown below.
  • the at least one leg 27 may be flexible. Further, it may be biased towards the central longitudinal axis. In the following, two second legs 27 are shown for exemplary purposes.
  • the distally directed surface (collar) 13 maybe substantially disk-shaped and provided extending from an internal circumferential surface of the housing 1.
  • the collar 13 may further have leg recesses 131 through which the second legs 27 extend. That is, the number of leg recesses 131 corresponds to the number of second legs 27.
  • the leg recesses 131 maybe provided as a circumferential cut-out in the collar 13.
  • the second legs 27 may thus extend between the collar 13 and an internal circumferential surface of the housing 1.
  • the leg recesses 131 may extend in a circumferential direction allowing rotational movement of the manually operable activator 2.
  • the second legs 27 may further comprise a first locking protrusion 271 and a second locking protrusion 272.
  • the first and second locking protrusions 271, 272 may be formed as hooks or the like.
  • the first and second locking protrusions 271, 272 may comprise a proximally directed chamfered surface and a flat distally directed surface.
  • Figs. 16A and 16B show cross sections of the manually operable activator 2 and the housing 1 (with the other elements being omitted), wherein Fig. 16A depicts the second rotational state (unlocked state) of the manually operable activator and Fig. 16B depicts the activated state (medicament delivery in process), in which the manually operable activator 2 has been pushed in the proximal direction.
  • the second legs 27 extend through the corresponding leg recesses 131 of the housing 1, wherein the first locking protrusion 271 abuts a proximally directed surface of the collar 13. That is, the flat distally directed surface of the first locking protrusion 271 may abut the collar 13. The first locking protrusion 271 may therefore prevent distal movement of the manually operable activator 2.
  • the second locking protrusion 272 snaps onto the proximally directed surface of the collar 13. That is, the flat distally directed surface of the second locking protrusion 272 may about the collar 13.
  • the chamfered surface of the second locking protrusion 272 may aid in overcoming the collar 13.
  • the legs 27 may be biased towards the central longitudinal axis and thus lock the manually operable activator 2 in the activated, i.e., pushed position. This may provide any indication that the device has been used.
  • the housing 1 may comprise an internal recess in which the second legs 27 may move in the longitudinal direction as well as the rotational direction.
  • Fig. 17 shows a perspective view of the housing 1 corresponding to the view of Fig. 3A.
  • the housing 1 as shown in Fig. 17 comprises the leg recess 131 described above.
  • a leg stop 132 may be provided inside the leg recess 131 which may be configured to prevent inadvertent rotation of the manually operable activator 2.
  • the (flexible) legs 27 need to overcome the leg stop 132.
  • the leg stop 132 corresponds to the proximally directed protrusion 18 shown in Fig. 2.
  • Fig. 18 shows a perspective view of the medicament delivery device without the rotation protrusion and the corresponding housing recess as described above.
  • Fig. 19 shows a perspective exploded view of a syringe holder 71 and a cap 8.
  • the cap 8 may comprise a substantially tubular member 81 extending in the distal direction.
  • the syringe holder 71 (cartridge carrier) of the medicament delivery device may further comprise at least one flexible syringe holder arm 711.
  • the flexible syringe holder arm 711 may extend in an outward direction, i.e., in a radial direction with respect to the central longitudinal axis.
  • the flexible syringe holder arm 711 may be flexible in the radial direction.
  • the flexible syringe holder arm 711 may be provided at or towards a proximal end of the syringe holder 71.
  • the syringe holder 71 may further comprise syringe holder ribs 712 configured to engage with the medicament delivery member cover 5.
  • Fig. 20 shows a cross sectional view of a proximal part of a medicament delivery device according to an embodiment in an assembled state.
  • the flexible syringe holder arms 711 (two arms in the depicted example) abut respective syringe holder recesses 14 in the housing 1, thus blocking proximal movement of the syringe holder 71.
  • the syringe holder recesses 14 may comprise respective shoulders provided on an inner circumferential surface of the housing 1 which the flexible syringe holder arms 711 abut.
  • the flexible syringe holder arms 711 are prevented from flexing inwards by the cap 8.
  • the tubular member 81 may be provided inside of the housing 1 and the syringe holder 71 (i.e., radially inwards with respect to the central longitudinal axis) and may thus hinder the flexible syringe holder arms 711 from flexing inwards and clearing the syringe holder recesses 14. Therefore, the syringe holder 71 cannot be moved in the proximal direction and the device cannot be activated.
  • the flexible syringe holder arms 711 prevent premature device activation. In other words, it is not possible to activate the device without first removing the cap 8.
  • the flexible syringe holder arms 711 maybe flexed inwards or they maybe flexed inwards by the chamfered syringe holder recess 14 when the syringe holder 71 is moved proximally for drug delivery.
  • Fig. 21 shows the proximal part of the medicament delivery device after injection and lock out of the device (needle not depicted). Locking of the medicament delivery member cover 5 after injection has been described above and will not be repeated. As shown in Fig. 15, the flexible syringe holder arms 711 remaining flexed in to allow drug delivery and lock out of the device.
  • Corresponding elements such as the internal locking surface 11 and the proximally directed surface 21, the housing recess 12 and the rotation protrusion 22, the distally directed surface 13 and the retaining element 43, etc. may all be provided in plural and in corresponding numbers.
  • the delivery devices described herein can be used for the treatment and/ or prophylaxis of one or more of many different types of disorders.
  • Exemplary disorders include, but are not limited to: rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis), hypercholesterolaemia and/or dyslipidemia, cardiovascular disease, diabetes (e.g.
  • psoriasis psoriatic arthritis
  • spondyloarthritis hidradenitis suppurativa
  • Sjogren's syndrome migraine, cluster headache, multiple sclerosis, neuromyelitis optica spectrum disorder, anaemia, thalassemia, paroxysmal nocturnal hemoglobinuria, hemolytic anaemia, hereditary angioedema, systemic lupus erythematosus, lupus nephritis, myasthenia gravis, Behqet's disease, hemophagocytic lymphohistiocytosis, atopic dermatitis, retinal diseases (e.g., age-related macular degeneration, diabetic macular edema), uveitis, infectious diseases, bone diseases (e.g., osteoporosis, osteopenia), asthma, chronic obstructive pulmonary disease, thyroid eye disease, nasal polyps, transplant, acute hypog
  • Exemplary types of drugs that could be included in the delivery devices described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, enzymes, vaccines, anticoagulants, immunosuppressants, antibodies, antibody-drug conjugates, neutralizing antibodies, reversal agents, radioligand therapies, radioisotopes and/or nuclear medicines, diagnostic agents, bispecific antibodies, proteins, fusion proteins, peptibodies, polypeptides, pegylated proteins, protein fragments, nucleotides, protein analogues, protein variants, protein precursors, protein derivatives, chimeric antigen receptor T cell therapies, cell or gene therapies, oncolytic viruses, or immunotherapies.
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, coagulation factors, enzymes, enzyme inhibitors, retinoids, steroids, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
  • immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, coagulation factors, enzymes, enzyme inhibitors, retinoids, steroids, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, those exhibiting a proposed mechanism of action, such as human epidermal growth factor receptor 2 (HER-2) receptor modulators, interleukin (IL) modulators, interferon (IFN) modulators, complement modulators, glucagon-like peptide-i (GLP-i) modulators, glucose-dependent insulinotropic polypeptide (GIP) modulators, cluster of differentiation 38 (CD38) modulators, cluster of differentiation 22 (CD22) modulators, Ci esterase modulators, bradykinin modulators, C-C chemokine receptor type 4 (CCR4) modulators, vascular endothelial growth factor (VEGF) modulators, B-cell activating factor (BAFF), P-selectin modulators, neonatal Fc receptor (FcRn) modulators, calcitonin gene-related peptide (CGRP) modulators, epidermal growth factor receptor (EGFR) modulators, cluster of differentiation 79B (CD79B
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to: etanercept, abatacept, adalimumab, evolocumab, exenatide, secukinumab, erenumab, galcanezumab, fremanezumab-vfrm, alirocumab, methotrexate (amethopterin), tocilizumab, interferon beta-ia, interferon beta-ib, peginterferon beta-ia, sumatriptan, darbepoetin alfa, belimumab, sarilumab, semaglutide, dupilumab, reslizumab, omalizumab, glucagon, epinephrine, naloxone, insulin, amylin, vedolizumab, eculizumab, ravulizumab, crizanlizuma
  • Exemplary drugs that could be included in the delivery devices described herein may also include, but are not limited to, oncology treatments such as ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, rituximab, trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan- nxki, pertuzumab, transtuzumab-pertuzumab, alemtuzumab, belantamab mafodotin- blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90-Yttrium-ibrit
  • Exemplary drugs that could be included in the delivery devices described herein include “generic” or biosimilar equivalents of any of the foregoing, and the foregoing molecular names should not be construed as limiting to the “innovator” or “branded” version of each, as in the non-limiting example of innovator medicament adalimumab and biosimilars such as adalimumab-afzb, adalimumab-atto, adalimumab-adbm, and adalimumab-adaz.
  • Exemplary drugs that could be included in the delivery devices described herein also include, but are not limited to, those used for adjuvant or neoadjuvant chemotherapy, such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
  • adjuvant or neoadjuvant chemotherapy such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
  • Exemplary chemotherapy drugs include, by way of example but not limitation, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed, mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.
  • Exemplary drugs that could be included in the delivery devices described herein also include, but are not limited to, analgesics (e.g., acetaminophen), antipyretics, corticosteroids (e.g. hydrocortisone, dexamethasone, or methylprednisolone), antihistamines (e.g., diphenhydramine or famotidine), antiemetics (e.g., ondansetron), antibiotics, antiseptics, anticoagulants, fibrinolytics (e.g., recombinant tissue plasminogen activator [r-TPA]), antithrombolytics, or diluents such as sterile water for injection (SWFI), 0.9% Normal Saline, 0.45% normal saline, 5% dextrose in water, 5% dextrose in 0.45% normal saline, Lactated Ringer’s solution, Heparin Lock Flush solution, 100 U/mL Heparin Lock Flush Solution, or
  • compositions including, but not limited to, any drug described herein are also contemplated for use in the delivery devices described herein, for example pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) and a pharmaceutically acceptable carrier.
  • Such formulations may include one or more other active ingredients (e.g., as a combination of one or more active drugs), or may be the only active ingredient present, and may also include separately administered or co-formulated dispersion enhancers (e.g. an animal-derived, human-derived, or recombinant hyaluronidase enzyme), concentration modifiers or enhancers, stabilizers, buffers, or other excipients.
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, a multi-medication treatment regimen such as AC, Dose-Dense AC, TCH, GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mFOLFOX6, mFOLFOXy, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R-CHOP, RCHOP-21, Mini-CHOP, Maxi-CHOP, VR-CAP, Dose-Dense CHOP, EPOCH, Dose-Adjusted EPOCH, R-EPOCH, CODOX-M, IVAC, HyperCVAD, R-HyperCVAD, SC-EPOCH-RR, DHAP, ESHAP, GDP, ICE, MINE, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CHP, GCVP, DHAX

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Environmental & Geological Engineering (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Un dispositif d'administration de médicament selon l'invention est conçu pour recevoir un récipient de médicament et un bloc d'alimentation conçu pour exercer une force sur ledit récipient de médicament pour expulser une dose de médicament. Un activateur actionnable manuellement (2) comprend au moins une butée (23) disposée au niveau d'une surface circonférentielle de celui-ci et un boîtier (1) comprend une surface de verrouillage interne (11). Dans un premier état de rotation de l'activateur actionnable manuellement (2), une surface dirigée de manière proximale (21) de l'activateur actionnable manuellement (2) vient en butée contre la surface de verrouillage (11) du boîtier (1) bloquant le mouvement proximal de l'activateur actionnable manuellement (2) par rapport au boîtier (1) et un élément de blocage (33) d'un actionneur (3) est configuré pour venir en butée contre la butée (23) bloquant ainsi le mouvement proximal de l'actionneur (3) par rapport à l'activateur actionnable manuellement (2). Dans un second état de rotation de l'activateur actionnable manuellement (2), la surface dirigée de manière proximale (21) de l'activateur actionnable manuellement (2) est configurée pour dégager la surface de verrouillage (11) du boîtier (1) et l'activateur actionnable manuellement (2) est libre d'être déplacé dans la direction proximale lors de l'application d'une force par un utilisateur.
PCT/EP2024/075788 2023-09-18 2024-09-16 Dispositif d'administration de médicament Pending WO2025061618A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202363539041P 2023-09-18 2023-09-18
US63/539,041 2023-09-18
EP23205945.1 2023-10-26
EP23205945 2023-10-26
US202463676473P 2024-07-29 2024-07-29
US63/676,473 2024-07-29

Publications (1)

Publication Number Publication Date
WO2025061618A1 true WO2025061618A1 (fr) 2025-03-27

Family

ID=92712395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/075788 Pending WO2025061618A1 (fr) 2023-09-18 2024-09-16 Dispositif d'administration de médicament

Country Status (1)

Country Link
WO (1) WO2025061618A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130060232A1 (en) * 2011-09-02 2013-03-07 Unitract Syringe Pty Ltd Automatic reconstitution for dual chamber syringe
US20140330216A1 (en) * 2013-05-01 2014-11-06 Unitract Syringe Pty Ltd Plunger-driven auto-injectors
WO2020143991A1 (fr) 2019-01-11 2020-07-16 Shl Medical Ag Dispositif d'administration de médicament
US20210077737A1 (en) * 2017-12-20 2021-03-18 Shl Medical Ag An activator for a medicament delivery device

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130060232A1 (en) * 2011-09-02 2013-03-07 Unitract Syringe Pty Ltd Automatic reconstitution for dual chamber syringe
US20140330216A1 (en) * 2013-05-01 2014-11-06 Unitract Syringe Pty Ltd Plunger-driven auto-injectors
US20210077737A1 (en) * 2017-12-20 2021-03-18 Shl Medical Ag An activator for a medicament delivery device
WO2020143991A1 (fr) 2019-01-11 2020-07-16 Shl Medical Ag Dispositif d'administration de médicament

Similar Documents

Publication Publication Date Title
EP4651923A1 (fr) Dispositif d'administration de médicament et ensemble d'administration de médicament
WO2025061618A1 (fr) Dispositif d'administration de médicament
WO2024126093A1 (fr) Dispositif de sécurité à injection pour administrer un médicament
WO2025228678A1 (fr) Sous-ensemble pour un dispositif d'administration de médicament
EP4646249A1 (fr) Dispositif d'administration de médicament
EP4646248A1 (fr) Dispositif d'administration de médicament
WO2025153310A1 (fr) Auto-injecteur
WO2025113819A1 (fr) Dispositif d'administration de médicament
WO2025176498A1 (fr) Ensemble capuchon pour un dispositif d'administration de médicament
WO2024146819A1 (fr) Dispositif d'administration de médicament
EP4661936A1 (fr) Sous-ensemble pour un dispositif d'administration de médicament, dispositif d'administration de médicament et procédé de fonctionnement d'un dispositif d'administration de médicament
EP4655031A1 (fr) Dispositif d'administration de médicament
WO2025157561A1 (fr) Sous-ensemble pour dispositif de délivrance de médicament
EP4655025A1 (fr) Dispositif d'administration de médicament
WO2025180828A1 (fr) Capuchon pour dispositif d'administration de médicament
EP4646252A1 (fr) Dispositif d'administration de médicaments
WO2024153448A1 (fr) Dispositif d'injection pour administration d'un médicament
WO2025098848A1 (fr) Ensemble pour dispositif d'administration de médicament
WO2025237664A1 (fr) Dispositif d'administration de médicament ayant un mécanisme de libération de tige de piston
EP4646247A1 (fr) Dispositif d'administration de médicament
WO2025153309A1 (fr) Auto-injecteur
WO2025113999A1 (fr) Dispositif d'administration de médicament
WO2025021934A1 (fr) Dispositif d'administration de médicament
WO2025051705A1 (fr) Ensemble d'entraînement pour dispositif d'administration de médicament
WO2024194029A1 (fr) Dispositif d'administration de médicament

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24768631

Country of ref document: EP

Kind code of ref document: A1